Development and Evaluation of Inhalable Dry Powder Formulations, 2nd Edition

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".

Deadline for manuscript submissions: 31 August 2025 | Viewed by 441

Special Issue Editors


E-Mail Website
Guest Editor
Transpire Bio Inc., Weston, FL, USA
Interests: pulmonary delivery; dry powder inhalations; targeted drug delivery systems; particle engineering; spray drying; surface characterization; physicochemical characterization; respirable size particle dissolution
Special Issues, Collections and Topics in MDPI journals

E-Mail Website1 Website2
Guest Editor
Departamento de Física, Matemáticas e Ingeniería, Universidad de Sonora, Campus Navojoa, Navojoa 85880, Sonora, Mexico
Interests: drug delivery; nanotechnology; drug inhalation; control release

Special Issue Information

Dear Colleagues,

Respiratory drug delivery is an important route for the administration of the treatment and prevention of diseases of the respiratory tract (nasal and pulmonary regions), and for delivering drugs non-invasively to the central nervous system (CNS). Pulmonary drug delivery has recently gained significant importance in the therapeutic field due to its various advantages, such as pain-free administration, targeted drug delivery with minimum systemic exposure, rapid onset of action, reduced enzymatic degradation, high drug concentrations in the lungs, and avoidance of hepatic first-pass metabolism when compared to the other conventional routes of administration. Formulations including biologicals have shown an increased stability when they are in solid-state rather than liquid formulations, making dry powder inhalers (DPIs) the more preferred formulation for pulmonary drug delivery. The aerodynamic diameter, along with other features of the particles, plays a key role in the deposition of aerosols in the lungs; therefore, it is important to engineer the particles using the right technique.

We are so happy that the first edition has published nine papers successfully, and most of them have been highly viewed and cited. To attract more attention from the community on this topic, we opened the second edition.

This Special Issue focuses on the design and development of innovative dry powder formulations as inhalation aerosols via lung and nasal routes of administration.

Dr. Basanth Babu Eedara
Dr. David Armando Encinas Basurto
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • respiratory delivery
  • dry powder inhalation
  • particle engineering design
  • physicochemical characterization
  • aerosolization
  • lung delivery
  • nasal delivery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 10850 KiB  
Article
Lipid–Polymer Hybrid Nanoparticles in Microparticle-Based Powder: Evaluating the Potential of Methylprednisolone Delivery for Future Lung Disease Treatment via Inhalation
by Cinzia Scialabba, Emanuela Fabiola Craparo, Sofia Bonsignore, Marta Cabibbo and Gennara Cavallaro
Pharmaceutics 2024, 16(11), 1454; https://doi.org/10.3390/pharmaceutics16111454 - 14 Nov 2024
Viewed by 338
Abstract
Background. Lipid–polymer hybrid nanoparticles (LPHNPs) offer a promising method for delivering methylprednisolone (MePD) to treat lung inflammation, addressing aggregation issues seen with polymer-only formulations. Objectives. This study aimed to develop LPHNPs for MePD delivery, assessing their physicochemical properties, drug loading, cytocompatibility, and release [...] Read more.
Background. Lipid–polymer hybrid nanoparticles (LPHNPs) offer a promising method for delivering methylprednisolone (MePD) to treat lung inflammation, addressing aggregation issues seen with polymer-only formulations. Objectives. This study aimed to develop LPHNPs for MePD delivery, assessing their physicochemical properties, drug loading, cytocompatibility, and release profiles, ultimately enabling inhalable microparticle-based powder. Methods. The nanoparticles were formulated using α,β-poly(N-2-hydroxyethyl)-DL-aspartamide-g-Rhodamine B-g-poly(lactic acid) (PHEA-g-RhB-g-PLA) and phospholipids DPPC, DOTAP, and DSPE-PEG2000 in a 45:30:25 weight ratio. Their size, redispersion after freeze-drying, drug loading (DL%), and controlled release were evaluated. Cytocompatibility was assessed on 16-HBE cell lines, measuring anti-inflammatory effects via IL-6 and IL-8 levels. Spray drying was optimized to produce microparticles using mannitol (MAN), leucine (LEU), and N-acetylcysteine (NAC). Results. The nanoparticles had a size of 186 nm and a DL% of 2.9% for MePD. They showed good cytocompatibility, significantly reducing IL-6 and IL-8 levels. Spray drying yielded microparticles with a fine particle fraction (FPF) of 62.3% and a mass median aerodynamic diameter (MMAD) of 3.9 µm. Inclusion of LPHNPs@MePD (0.25% w/v) resulted in FPF and MMAD values of 56.7% and 4.4 µm. In conclusion, this study described the production of novel inhalable powders as carriers for MePD-loaded nanostructures with favorable physicochemical properties, cytocompatibility, and promising aerosol performance, indicating their potential as an effective inhalable therapy for lung inflammation with corticosteroids, especially for treating chronic diseases. Full article
Show Figures

Figure 1

Back to TopTop